Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung ...

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Merck ...

After six days of gains, shares dropped, reflecting mixed momentum. See insights on earnings, cost-cutting, and analyst ...

Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now. On August 12, 2025, ...

The UK’s National Institute for Health and Care Excellence (NICE) has today (August 21) recommended the use of Japanese pharma major Astellas’ enfortumab vedotin with MSD’s Keytruda (pembrolizumab) ...

GMO’s 13F portfolio grew to $33.23B in Q2 2025, with Microsoft, Meta, Alphabet, Oracle, and Apple as top holdings. Read more about the portfolio here.

Additionally, a study published in July 2025 examined the use of methotrexate as first-line treatment for pulmonary ...

CHENNAI: Agriculture Minister MRK Panneerselvam dismissed the charges levelled by PMK leader Anbumani Ramadoss that Chief ...

Merck & Co., Inc. (NYSE: MRK) is one of the best depressed stocks to buy in 2025. On August 2, the company completed the ...

Skyhawk's RNA tech could be Merck's next blockbuster play as drug setbacks and looming patent cliffs force a reinvention.

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Merck & Co., Inc. (NYSE:MRK) is one of ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...